[
    [
        {
            "time": "2020-05-19",
            "original_text": "【主力资金】扫货芯片股，资金疯抢的名单来了",
            "features": {
                "keywords": [
                    "主力资金",
                    "芯片股",
                    "资金疯抢"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "半导体"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "【主力资金】扫货芯片股，资金疯抢的名单来了",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "复星医药参与设立私募股权并投资基金-亚汇网",
            "features": {
                "keywords": [
                    "复星医药",
                    "私募股权",
                    "投资基金"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药参与设立私募股权并投资基金-亚汇网",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "福布斯最新上市公司2000强：CVS超辉瑞成新霸主！16家中国药企入围，翰森超越中生",
            "features": {
                "keywords": [
                    "福布斯",
                    "上市公司2000强",
                    "CVS",
                    "辉瑞",
                    "中国药企",
                    "翰森",
                    "中生"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "福布斯最新上市公司2000强：CVS超辉瑞成新霸主！16家中国药企入围，翰森超越中生",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "最少翻4倍！美股新冠疫苗龙头有哪些？",
            "features": {
                "keywords": [
                    "美股",
                    "新冠疫苗",
                    "龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "最少翻4倍！美股新冠疫苗龙头有哪些？",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "复星医药(600196.SH)：利妥昔单抗注射液新增两项适应症获药品注册审评受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "利妥昔单抗",
                    "注射液",
                    "适应症",
                    "药品注册审评受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：利妥昔单抗注射液新增两项适应症获药品注册审评受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "16家中国药企上榜2020年“全球上市公司2000强”",
            "features": {
                "keywords": [
                    "中国药企",
                    "全球上市公司2000强"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "16家中国药企上榜2020年“全球上市公司2000强”",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "多么痛的领悟，你瞧不上的这270只个股股价已经超越五年前！",
            "features": {
                "keywords": [
                    "个股",
                    "股价",
                    "五年前"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "多么痛的领悟，你瞧不上的这270只个股股价已经超越五年前！",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "时代热评 | 陈启宇任上猛增178倍，复星医药近百亿商誉压顶",
            "features": {
                "keywords": [
                    "复星医药",
                    "陈启宇",
                    "商誉"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "时代热评 | 陈启宇任上猛增178倍，复星医药近百亿商誉压顶",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "康方生物升3% 中生制药上涨2% 细胞癌新药临床试验佳",
            "features": {
                "keywords": [
                    "康方生物",
                    "中生制药",
                    "细胞癌",
                    "新药",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康方生物升3% 中生制药上涨2% 细胞癌新药临床试验佳",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "恒生指数高开2.32%报24489点 蓝筹股全线扬创科实业(00669)升4.98%",
            "features": {
                "keywords": [
                    "恒生指数",
                    "蓝筹股",
                    "创科实业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒生指数高开2.32%报24489点 蓝筹股全线扬创科实业(00669)升4.98%",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "智通港股通占比异动统计|5月19日",
            "features": {
                "keywords": [
                    "智通",
                    "港股通",
                    "占比",
                    "异动"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通占比异动统计|5月19日",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 5,
                "Source_Recency": 10
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "智通港股通持股解析|5月19日",
            "features": {
                "keywords": [
                    "智通",
                    "港股通",
                    "持股"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通持股解析|5月19日",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 5,
                "Source_Recency": 10
            }
        },
        {
            "time": "2020-05-19",
            "original_text": "【华西医药崔文亮团队】《医药生物行业点评报告：两会医药议题解读：疫苗、创新药、IVD和医疗设备等领域继续成为关注焦点》",
            "features": {
                "keywords": [
                    "华西医药",
                    "两会",
                    "医药议题",
                    "疫苗",
                    "创新药",
                    "IVD",
                    "医疗设备"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "【华西医药崔文亮团队】《医药生物行业点评报告：两会医药议题解读：疫苗、创新药、IVD和医疗设备等领域继续成为关注焦点》",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-05-17",
            "original_text": "【山证医药】医药行业周报（20200517）：注射剂一致性评价正式文件出台，行业格局面临巨变",
            "features": {
                "keywords": [
                    "山证医药",
                    "医药行业",
                    "注射剂",
                    "一致性评价",
                    "行业格局"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【山证医药】医药行业周报（20200517）：注射剂一致性评价正式文件出台，行业格局面临巨变",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]